Prostate-specific membrane antigen radioligand therapy of prostate cancer

Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still chal-lengina in routine clinical practice. Prostate-specific membrane antigen (PSMA) targeted radionuclide therapy with beta- or alpha-emitters such as 177-Lutethium (Lu-177) or 225-Actinium ((225)A) has been a main focus at multiple academic research centers in the last few years. This review article provides an overview of PSMA characteristics. clinical performance, safety and toxicity of PSMA targeted beta- or alpha-radiation therapy.